Beschreibung:
Van Kempen et al. described high natalizumab concentrations in their natalizumab-treated multiple sclerosis (MS) patients at time of re-dosing. Based on the literature research the authors consider anatalizumab concentration above 2 μg/mL to be sufficient for an adequate alpha-4 integrin receptor saturation of above 70%.Recently, we have demonstrated similar results using our new cell-based immunoassay to evaluate free natalizumab concentration, cell-bound natalizumab, and alpha-4 integrin receptor saturation as the key pharmacokinetic/pharmacodynamic parameters of natalizumab treatment in different in vivo settings. We investigated the effects of treatment interval extension or treatment cessation.